O,O',O''-(methylsilylidyne)trioxime 2-pentanone

Developmental toxicity / teratogenicity

Administrative data

Endpoint:

developmental toxicity

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: OECD guidance study conducted under GLP

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2012

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

other: OECD422

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Test material

Test material information

Constituent 1

Reference substance name:

623-40-5

Cas Number:

623-40-5

IUPAC Name:

623-40-5

Test material form:

other: liquid

Test animals

Species:

rat

Strain:

Sprague-Dawley

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Charles River (UK) Ltd.
- Age at study initiation: 71 days
- Weight at study initiation: 337 g to 394 g (males), 220 g to 271 g (females)
- Fasting period before study: none
- Housing: Animals were housed inside a barriered rodent facility. The gridded cages used during pairing were suspended over trays covered with absorbent paper which was changed daily. For cages with solid floors, wood based material was used as bedding and was sterilised by autoclaving and changed at least twice each week. Cages, cage-trays, food hoppers and water bottles were changed at appropriate intervals. The cages were distributed on the racking to equalise, as far as possible, environmental influences amongst the groups.
- Diet (e.g. ad libitum): ad libitum (SDS VRF1 Certifie Diet) except overnight before routine blood sampling. This diet contained no added antibiotic or other chemotherapeutic or prophylactic agent.
- Water (e.g. ad libitum): ad libitum from the public supply via polycarbonate or polypropylene bottles fitted with sipper tubes.
- Acclimation period: 6 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 to 23
- Humidity (%): 40 to 70
- Air changes (per hr): Each animal room was kept at positive pressure with respect to the outside by its own supply of filtered fresh air, which was passed to atmosphere and not re-circulated.
- Photoperiod (hrs dark / hrs light): 12 hrs dark / 12 hrs light

IN-LIFE DATES: From: To: 21 March 2012 to 23 May 2012

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

corn oil

Details on exposure:

PREPARATION OF DOSING SOLUTIONS:
The test substance, MPKO, was prepared for administration as a series of graded concentrations in the vehicle, by dilution of individual weighings of the test substance. Small amounts of vehicle were added to the test substance and mixed until a solution was formed. This was made up to the required volume with vehicle and then magnetically stirred until homogenous. The test substance was used as supplied. All formulations were prepared weekly and stored refrigerated before use.


VEHICLE
- Concentration in vehicle: 7.5, 25, 75 mg/mL
- Amount of vehicle (if gavage): 2 mL/kg bw

Analytical verification of doses or concentrations:

yes

Details on analytical verification of doses or concentrations:

Before treatment commenced, the suitability of the proposed mixing procedure was determined and specimen formulations were analysed to assess the homogeneity and stability of the test material in the liquid matrix. Specimen formulations (typically 400 mL) were prepared at concentrations of 1 mg/mL and 100 mg/mL and equally split between four amber screw-capped bottles. Prior to initial sampling on each day, the formulation was mixed by 20-fold inversion. A control vehicle sample was stored with each batch of stability samples. The stability was confirmed for at least 24 hours at ambient temperature and for up to 15 days when refrigerated (2-8¿C).
Samples of each formulation prepared for administration on the first and last occasion of treatment were analysed for achieved concentration of the test substance. Four samples were taken (nominally 1 mL accurately weighed) from all groups. Two of the samples from each group were analysed. The remainder were retained as contingency for analysis if any result required confirmation.

Details on mating procedure:

- Impregnation procedure: cohoused
- If cohoused:
- M/F ratio per cage: 1:1
- Length of cohabitation: maximum of 2 weeks
- Further matings after two unsuccessful attempts: no
- Verification of same strain and source of both sexes: yes
- Proof of pregnancy: vaginal plug / sperm in vaginal smear referred to as day 0 of pregnancy
- Any other deviations from standard protocol: No

Duration of treatment / exposure:

The test substance, MPKO, was administered for two weeks before pairing up to necropsy (at least five weeks) for males and two weeks before pairing then throughout pairing and gestation until Day 6 of lactation for females. Recovery animals were treated for approximately six weeks and completed a further 14 days without treatment.

Animals of the F1 generation were not dosed.

Frequency of treatment:

All animals were dosed once each day at approximately the same time each day, seven days per week.

Doses / concentrations

Remarks:

Doses / Concentrations:
15, 50, 150 mg/kg bw/day
Basis:
other: actual administered

No. of animals per sex per dose:

10 males per group (Groups 1 to 4)
15 females (Groups 1 and 4), of these 5 females per group were not mated and were used for the recovery group
10 females (Groups 2 and 3)

Control animals:

yes, concurrent vehicle

Details on study design:

Ten males and 10 females per group were treated for two weeks at dose levels of 15, 50 or 150 mg/kg/day before pairing. Treatment continued to a total of at least 5 weeks. A control group of 10 male and 10 female rats received the vehicle, corn oil, at the same volume-dose throughout the same period. Males were killed after at least 5 weeks of treatment and females were killed on Day 7 of lactation.
Recovery, over 14 days without treatment, was assessed in five of the control and five of the high dose males and in an extra five unmated females in the same groups which were treated for 6 weeks before start of recovery.
The F1 generation received no direct administration of the test substance; any exposure was in utero or via the milk.
During the study, clinical condition, detailed physical and arena observations, sensory reactivity, grip strength, motor activity, bodyweight, food consumption, gestation length and parturition observations, haematology, blood chemistry, organ weight, macropathology and histopathology investigations were undertaken. The clinical condition, litter size and survival, sex ratio and bodyweight of all offspring were assessed.

Examinations

Maternal examinations:

CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Daily during the first week of treatment and weekly thereafter for all animals and on Days 0, 6, 13 and 20 after mating and Days 1 and 6 of lactation for mated females only

DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Before treatment commenced and during each week of treatment and recovery periods for each adult and on Days 0, 6, 13 and 20 after mating and Days 1 and 6 of lactation for Main study females only.

BODY WEIGHT: Yes
- Time schedule for examinations: On the day that treatment commenced (Week 0), weekly thereafter for the treatment and recovery periods and before necropsy. The weight of each Main study female was also recorded on Days 0, 6, 13 and 20 after mating and on Days 1, 4 and 7 of lactation.


FOOD CONSUMPTION: Yes
- The weight of food supplied to each cage, that remaining and an estimate of any spilled was recorded on a weekly basis. The males had no food consumption performed in Week 3 due to pairing. The Main study females were recorded on a weekly basis until they were paired for mating. From these records the mean weekly consumption per animal (g/rat/week) was calculated for each cage.
For each Main study female, the weight of food supplied, that remaining and an estimate of any spilled was also recorded for the periods Days 0-5, 6-12 and 13-19 after mating and Days 1-3 and 4-6 of lactation. From these records the mean daily consumption (g/rat/day) was calculated for each animal.


OPHTHALMOSCOPIC EXAMINATION: No


HAEMATOLOGY: Yes
- Time schedule for collection of blood: Week 2 and Recovery Week 2
- Anaesthetic used for blood collection: Yes, isofluorane
- Animals fasted: Yes
- How many animals: 5/sex
- Parameters checked included thoses listed in the OECD guidance.

CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Week 2 and Recovery Week 2
- Animals fasted: Yes
- How many animals: 5/sex
- Parameters checked included those listed int eh OECD guidance.

URINALYSIS: No

NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: During Week 5 (males), Days 4-6 of lactation (females)
- Dose groups that were examined: Groups 1, 2, 3, and 4
- Battery of functions tested: sensory activity / grip strength / motor activity

Ovaries and uterine content:

The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: No
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: No
- Other:

Fetal examinations:

- External examinations: Yes: all per litter
- Soft tissue examinations: No
- Skeletal examinations: No
- Head examinations: No

Statistics:

All statistical analyses were carried out separately for males and females. For litter/fetal findings the litter was taken as the treated unit and the basis
for statistical analysis and biological significance was assessed with relevance to the severity of the anomaly and the incidence of the finding within the background control population.

Indices:

Post-implantation survival index (%), live birth index (%), viability index(%)

Results and discussion

Results: maternal animals

Maternal developmental toxicity

Details on maternal toxic effects:

Maternal toxic effects:yes

Details on maternal toxic effects:
CLINICAL SIGNS AND MORTALITY
There were no unscheduled deaths and no post dosing signs.

BODY WEIGHT AND WEIGHT GAIN
There were no adverse bodyweight effects in males or females before or after mating, during lactation and during recovery.

FOOD CONSUMPTION
Food consumption was not affected by treatment with MPKO.

HAEMATOLOGY
Treatment with MPKO at 50 and 150 mg/kg/day was associated with major adverse effects upon the red blood cells and the following changes were attributed to treatment. Males and females receiving 50 and 150 mg/kg/day showed low haematocrit and haemoglobin levels, low red blood cell counts, high reticulocytes and low mean cell haemoglobin concentrations, and for males only at those dose levels high mean cell volumes., aA dose relationship was also apparent. The high mean cell volume in females was restricted to those receiving 150 mg/kg/day. High mean cell haemoglobin levels and high platelet levels in males and females receiving 150 mg/kg/day were also evident.

After the 14 day off dose period many of the parameters noted to be different to control during treatment had shown complete recovery. Those changes which had not completely resolved included high mean cell haemoglobin level, low mean cell haemoglobin concentration and high mean cell volumes for males previously receiving 150 mg/kg/day, low red blood cell counts, high mean cell haemoglobin level and high mean cell volume for females previously receiving the same dose.

CLINICAL CHEMISTRY
High bilirubin concentrations were recorded for males and females at 50 and 150 mg/kg/day during the week 2 of the treatment period. There was a suggestion of an increase in potassium and phosphorus in males receiving 150 mg/kg/day. Total protein was low for males attaining statistical significance for those receiving 50 and 150 mg/kg/day and albumin for males at 150 mg/kg/day was also low. Females receiving 150 mg/kg/day had a high Albumin/Globulin ratio.

The affected parameters were similar to control following two weeks of recovery.

NEUROBEHAVIOUR
Sensory reactivity findings and grip strength values for males and females were unaffected by treatment with MPKO.
There was no effect of MPKO on motor activity scores.

PRE-COITAL INTERVAL
All animals mated within the first four days following pairing

MATING PERFORMANCE AND FERTILITY
Percentage mating, conception rate and fertility index scores for all groups were 100%.

GESTATION LENGTH, PARTURITION, AND GESTATION INDEX
Gestation length was within the expected range for this strain for of rat at these laboratories. Two females, one each receiving 50 and 150 mg/kg/day, found to have implantation scars at necropsy on Day 25 of gestation but were not observed to give birth either due to total litter resorption or cannibalising pups born overnight prior to the first check of the day: a relationship to treatment is not inferred.

ORGAN WEIGHTS
Adjusted mean spleen weight was higher than Control in males and females receiving 50 or 150 mg/kg/day (X1.6 or X3.2 of Control for males and X1.3 and X2.5 of Control for females) with a dose response evident. In females receiving 150 mg/kg/day there was a slight increase in adjusted mean heart weight (X1.1 of Control).

After 14 days recovery, the spleen weights were still slightly higher than Control values for males and females which had received 150 mg/kg/day (X1.5 for males and X1.2 for females of Control); although no statistical significance was attained for females, and the values were lower than the main study animals. The heart weights of females receiving 150 mg/kg/day were similar to control values. Kidney weights were slightly higher than Control after the recovery period in males that had received 150 mg/kg/day (X1.1 of Control) this was not seen in the main phase animals.

GROSS PATHOLOGY
Enlarged spleen was seen in all males and females treated with 150 mg/kg/day and in three out of 10 males treated with 50 mg/kg/day. Dark colouration of the spleen was also seen in all males and females treated with 150 mg/kg/day, in nine out of 10 males and females treated with 50 mg/kg/day and in one out of 10 males treated with 15 mg/kg/day.

Dark colouration of the kidneys (left and right) was seen in nine females treated with 150 mg/kg/day and in three females treated with 50 mg/kg/day.

After the recovery period, dark colouration of the spleen was seen in three males and two females treated with 150 mg/kg/day

HISTOPATHOLOGY: NON-NEOPLASTIC
Spleen: Haemosiderosis was observed in males and females treated at 15, 50 and 150 mg/kg/day. Congestion was also seen in males and females treated at 50 and 150 mg/kg/day. An increase in the incidence of extramedullary haemopoiesis was also observed in males and females treated at 150 mg/kg/day. These changes revealed dose-relationship.
Liver: Extramedullary haemopoiesis was observed in males and females treated at 50 and 150 mg/kg/day.

After Recovery Period:
Spleen: An increase in the severity of haemosiderosis was observed in males and females previously treated at 150 mg/kg/day. A decrease in severity of congestion was also observed in males previously treated at 150 mg/kg/day

Results (fetuses)

Details on embryotoxic / teratogenic effects:

Embryotoxic / teratogenic effects:no effects

Details on embryotoxic / teratogenic effects:
There were no effects on any of the developmental endpoints assessed.

Effect levels (fetuses)

Dose descriptor:

NOEL

Effect level:

150 mg/kg bw/day (actual dose received)

Based on:

test mat.

Basis for effect level:

other: teratogenicity

Fetal abnormalities

Abnormalities:

not specified

Overall developmental toxicity

Developmental effects observed:

not specified

Applicant's summary and conclusion

Conclusions:

There were no adverse effects of treatment on the developmental screening parameters assessed up to 150 mg/kg bw/day, the highest dose tested.